Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Taiwan's updated civil defense guide focuses on wartime scenarios
09/16/2025 05:20 PM - Business
Taiwan shares close at new high as TSMC hits record
09/16/2025 05:20 PM - Science & Tech
MediaTek adopts TSMC's 2nm process for new flagship chip
09/16/2025 04:55 PM - Society
Danjiang Bridge sees last span being installed
09/16/2025 04:54 PM - Business
U.S. dollar closes sharply lower on Taipei forex market
09/16/2025 04:11 PM